drugset / Trial / NCT02957331

Beta Blockade in in Traumatic Brain Injury

NCT02957331

Phase 4 Completed 26 enrolled University of Tennessee
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is test the effect of beta-adrenergic blockade on mortality in patients with traumatic brain injury with the hypothesis being that the addition of beta blockade to the treatment regime of this patient population will lower mortality and supress the catecholamine surge that accompanies traumatic brain injury as compared to those who do not receive beta blockade. Half the patients will be randomized to receive propranolol and half will be randomized to receive no beta blocker.

Timeline

Start
2016-01
Primary completion
2018-05
Completion
2018-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 20 mg